Mostrar el registro sencillo del ítem

dc.contributor.authorRubio Antolin, Ana Rosa 
dc.contributor.authorGonzález, Rocío
dc.contributor.authorBusto Vázquez, Natalia 
dc.contributor.authorVaquero Gutiérrez, Mónica 
dc.contributor.authorIglesias, Ana L.
dc.contributor.authorJalón, Félix A.
dc.contributor.authorEspino Ordóñez, Gustavo 
dc.contributor.authorRodríguez, Ana M.
dc.contributor.authorGarcía Ruiz, Begoña 
dc.contributor.authorManzano, Blanca R. .
dc.date.accessioned2022-09-01T08:24:11Z
dc.date.available2022-09-01T08:24:11Z
dc.date.issued2021-09
dc.identifier.issn1999-4923
dc.identifier.urihttp://hdl.handle.net/10259/6825
dc.description.abstractAn important challenge in the field of anticancer chemotherapy is the search for new species to overcome the resistance of standard drugs. An interesting approach is to link bioactive ligands to metal fragments. In this work, we have synthesized a set of p-cymene-Ru or cyclopentadienyl-M (M = Rh, Ir) complexes with four chrysin-derived pro-ligands with different -OR substituents at position 7 of ring A. The introduction of a piperidine ring on chrysin led to the highly cytotoxic pro-ligand HL4 and its metal complexes L4-M (SW480 and A549 cell lines, cytotoxic order: L4-Ir > L4-Ru ≈ L4-Rh). HL4 and its complexes induce apoptosis and can overcome cis-platinum resistance. However, HL4 turns out to be more cytotoxic in healthy than in tumor cells in contrast to its metal complexes which displayed higher selectivity than cisplatin towards cancer cells. All L4-M complexes interact with double stranded DNA. Nonetheless, the influence of the metal is clear because only complex L4-Ir causes DNA cleavage, through the generation of highly reactive oxygen species (1O2 ). This result supports the hypothesis of a potential dual mechanism consisting of two different chemical pathways: DNA binding and ROS generation. This behavior provides this complex with a great effectivity in terms of cytotoxicityen
dc.description.sponsorshipSpanish Ministerio de Ciencia, Innovación y UniversidadesFEDER (RTI2018-100709-B-C21 and RTI2018-102040-B-100), Junta de Comunidades de CastillaLa Mancha-FEDER (JCCM) (grant SBPLY/19/180501/000260), Junta de Castilla y León-FEDER (BU087G19 and BU305P18), “la Caixa” Foundation (LCF/PR/PR12/11070003), as well as by UCLMFEDER (grants 2019-GRIN-27183 and 2019-GRIN-27209).en
dc.format.mimetypeapplication/pdf
dc.language.isoenges
dc.publisherMDPIes
dc.relation.ispartofPharmaceutics. 2021, V. 13, n. 10, 1540es
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectChrysin ligandsen
dc.subjectIridiumen
dc.subjectRutheniumen
dc.subjectRhodiumen
dc.subjectCanceren
dc.subjectMetallodrugsen
dc.subjectPiperidineen
dc.subjectHalf-sandwichen
dc.subject.otherBioquímicaes
dc.subject.otherBiochemistryen
dc.subject.otherQuímica inorgánicaes
dc.subject.otherChemistry, Inorganicen
dc.subject.otherQuímica físicaes
dc.subject.otherChemistry, Physical and theoreticalen
dc.titleAnticancer Activity of Half-Sandwich Ru, Rh and Ir Complexes with Chrysin Derived Ligands: Strong Effect of the Side Chain in the Ligand and Influence of the Metalen
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.relation.publisherversionhttps://doi.org/10.3390/pharmaceutics13101540es
dc.identifier.doi10.3390/pharmaceutics13101540
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-100709-B-C21/ES/NUEVOS METALOFARMACOS DISEÑADOS PARA INCREMENTAR LA SELECTIVIDAD EN TRATAMIENTOS CONTRA EL CANCER. USO DE FOTOTERAPIA Y VEHICULIZACION CON LIGANDOS DIRIGIDOS A TUMORESes
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-102040-B-I00/ES/PROPIEDADES ANTIMICROBIANAS DE NUEVOS COMPLEJOS ORGANOMETALICOSes
dc.relation.projectIDinfo:eu-repo/grantAgreement/JCCM//SBPLY%2F19%2F180501%2F000260es
dc.relation.projectIDinfo:eu-repo/grantAgreement/Junta de Castilla y León//BU087G19es
dc.relation.projectIDinfo:eu-repo/grantAgreement/Junta de Castilla y León//BU305P18es
dc.relation.projectIDinfo:eu-repo/grantAgreement/Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona//LCF%2FPR%2FPR12%2F11070003es
dc.relation.projectIDinfo:eu-repo/grantAgreement/UCLM//2019-GRIN-27183es
dc.relation.projectIDinfo:eu-repo/grantAgreement/UCLM//2019-GRIN-27209es
dc.identifier.essn1999-4923
dc.journal.titlePharmaceuticsen
dc.volume.number13es
dc.issue.number10es
dc.page.initial1540es
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones


Ficheros en este ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem